Russian Ancestry Groups: Type 2 Diabetes Differences

TL;DR Comparison

Group or contrast	T2D / carbohydrate disorder prevalence	T2D phenotype in Markelova et al.	Blood / lipid / BP differences in T2D	Immunity / inflammation evidence	Interpretation for PBMC paper
Chechens / North Caucasus peoples	Kononenko et al. found North Caucasus peoples had the lowest carbohydrate-metabolism disorder frequency among broad Russian ethnic categories: 15.6% overall; 13.9% in historical territories.1	Chechens had higher obesity-related pPGS than Yakuts and higher BMI/body-size traits overall.2 One Chechen-specific T2D association was SHBG-LpA pPGS with T2D odds (OR 4.64), but sample size was small.2	Within T2D, Chechen ancestry was associated with lower hip circumference, systolic BP, and HDL versus Tatar ancestry.2	No direct Chechen PBMC or cytokine evidence found.	Chechen/North Caucasus findings raise a hypothesis of different BMI-glycemia relationships; test whether PBMC inflammation tracks BMI, glycemia, medication, ascertainment, or unmeasured confounders.21
Tatars / Volga peoples	Kononenko et al. found Volga peoples had the highest carbohydrate-metabolism disorder frequency: 31.2%; 32.5% in historical territories, higher than Russians in the same regions.1	Tatars had lower WHR/WC/dBP than Chechens/Yakuts and the lowest Hyper Insulin and SHBG-LpA pPGS values in Markelova et al.2	In Markelova et al., Tatar ancestry within T2D was associated with the lowest total cholesterol and atherogenic index and highest systolic BP among the three groups.2	Tatar studies link CRP/TNF/TNFRSF1B variants to MetS and hsCRP/TNF-alpha/insulin resistance; chemokine loci CCL20 and CCL5 were associated with T2D.34	Strongest external T2D-immune support is Tatar-specific candidate-gene evidence involving chemokines and inflammatory markers; useful for pathway prioritization, not direct PBMC state claims.34
Yakuts / Sakha	Older rural Yakut data found no diabetes and low fasting glucose; broader northern Siberian data reported very low diagnosed T2D in northern indigenous peoples.56 Newer Yakutia studies show rising MetS with lifestyle transition.7	Yakut T2D patients had higher Beta Cell 1, Hyper Insulin, and Liver-Lipid pPGS and lower Obesity pPGS than other groups, consistent with a beta-cell/lipid-mechanism hypothesis and with population-level East Asian T2D patterns.28	Within T2D, Yakut ancestry was associated with lower systolic and diastolic BP but higher LDL, total cholesterol, and atherogenic index versus Tatar ancestry.2	Direct Yakut T2D immune-cell evidence is lacking. Blood/serum-marker studies show population-specific serological genetics, not T2D immunity.9	Yakuts may be the key contrast group for testing beta-cell/lipid pPGS versus obesity/IR pPGS associations with PBMC changes; do not treat pPGS profile as proof of active disease mechanism without clinical validation.28
Russia-wide ethnic categories	Volga peoples highest and North Caucasus peoples lowest carbohydrate-metabolism disorder prevalence in NATION sub-analysis; Mongoloid and Volga groups showed stronger risk-factor contributions for age >45, abdominal obesity, and grade 1 obesity.1	Not directly available across all Russian groups.	Broad group-level differences depend on geography and historical territory, not just ancestry.1	No broad Russian PBMC immune comparison found.	Published epidemiology supports ancestry/ethnicity-aware modeling but cannot replace same-cohort PBMC analysis.12

Bottom Line

The strongest T2D-specific evidence says Russian ancestry groups differ in prevalence, risk-factor architecture, and pPGS-defined mechanism profiles.²¹ Markelova et al. show Chechen/Tatar/Yakut differences in T2D mechanism pPGS distributions: Yakuts are more beta-cell/lipid-pPGS enriched and less obesity-pPGS enriched, while Chechens and Tatars are relatively more obesity/insulin-resistance-like.² Kononenko et al. show broad ethnic differences in carbohydrate-metabolism disorder prevalence across Russia, with Volga peoples highest and North Caucasus peoples lowest.¹ Direct ancestry-stratified PBMC immune evidence for T2D is still missing; the most relevant immune-related evidence is Tatar candidate-gene work implicating CRP/TNF/TNFRSF1B and chemokine genes in MetS/T2D.³⁴

Detailed Findings

Markelova et al. 2025: Same-Cohort Chechen/Tatar/Yakut T2D Mechanism Differences

Markelova et al. 2025 genotyped 275 participants from three Russian ancestry groups: Chechens, Tatars, and Yakuts.² Each group included healthy donors and 30 T2D patients.² Genetic ancestry was validated by PCA and ADMIXTURE, and partitioned polygenic scores (pPGS) were calculated for 12 T2D mechanism clusters.²

Key T2D-relevant findings:

• Yakut T2D patients had higher pPGS for Beta Cell 1, Hyper Insulin, and Liver-Lipid clusters and lower Obesity pPGS than other groups.²
• Across the whole cohort adjusted for T2D status, Yakuts had higher Beta Cell 1, Hyper Insulin, and SHBG-LpA pPGS than Tatars and the lowest Obesity pPGS.²
• Chechens had higher Beta Cell 1 pPGS than Tatars but lower than Yakuts.²
• Tatars had the lowest Hyper Insulin and SHBG-LpA pPGS.²
• pPGS did not generally distinguish T2D patients from healthy participants, except Chechen SHBG-LpA pPGS with T2D odds ratio 4.64; the authors caution that sample size was limited and pPGS were mechanism scores rather than diagnostic scores.²

Interpretation: Yakut pPGS distributions are consistent with a beta-cell/lipid-mechanism hypothesis and resemble patterns described in East Asian T2D literature, while Chechen/Tatar pPGS patterns are closer to western Eurasian obesity/insulin-resistance hypotheses.²⁸ This is the most directly relevant source because it uses the same cohort backbone as the PBMC ancestry project, but pPGS profiles still require clinical or molecular validation before being described as active disease mechanisms.²

Markelova et al. 2025: T2D-Conditioned Clinical Differences

The ancestry-by-T2D interaction analysis in Markelova et al. found that most within-T2D differences were in blood clinical parameters rather than anthropometrics.²

• Chechen ancestry within T2D was associated with lower hip circumference, lower systolic BP, and lower HDL compared with Tatar ancestry.²
• Yakut ancestry within T2D was associated with lower systolic BP and diastolic BP but higher LDL, total cholesterol, and atherogenic index compared with Tatar ancestry.²
• Tatar ancestry within T2D was associated with lowest total cholesterol and atherogenic index and highest systolic BP among the three groups.²

These findings support ancestry-aware modeling of lipid and blood-pressure variables when testing PBMC immune differences, because lipid/BP differences may mediate or confound immune-state differences.²¹⁰

Kononenko et al. 2022: Russian Ethnic Differences In Carbohydrate-Metabolism Disorders

Kononenko et al. 2022 performed a sub-analysis of the NATION epidemiological study.¹ It grouped self-reported nationalities into broad anthropological/ethnic categories: Mongoloid population, Peoples of the Volga region, Peoples of the North Caucasus, Peoples of Transcaucasia, and Russians.¹

Key findings:

• Highest carbohydrate-metabolism disorder frequency was in Peoples of the Volga region: 31.2%.¹
• Lowest frequency was in Peoples of the North Caucasus: 15.6%.¹
• Volga peoples living in historical territories had higher disorder prevalence than Russians living in the same regions: 32.5% versus 24.3%.¹
• North Caucasus peoples living in historical territories had lower prevalence than Russians of the Central Federal District: 13.9% versus 27.36%.¹
• North Caucasus peoples living in historical territories also had lower prevalence than North Caucasus peoples living elsewhere in Russia: 13.9% versus 21.95%.¹
• BMI was significantly lower in Volga peoples than in North Caucasus peoples.¹
• Age >45, abdominal obesity, and grade 1 obesity were more often linked to carbohydrate-metabolism disorders in Mongoloid and Volga groups than in North Caucasus and Transcaucasus groups.¹

Interpretation: Russian ethnic categories differ not only in T2D/pre-diabetes burden but also in how standard risk factors map onto carbohydrate-metabolism disorders.¹ This supports the paper’s need to model ancestry/ethnicity and risk factors together rather than treating BMI, glucose, or T2D as exchangeable across groups.¹

Yakut / Northern Siberian T2D and Metabolic Transition Evidence

Snodgrass et al. 2010 studied rural Yakut adults and found low fasting glucose, low MetS prevalence, and no diabetes cases.⁵ The result is consistent with a historically low-glycemia profile in a physically active high-latitude population.⁵ However, the same paper warned that increasing obesity and market-food consumption could raise impaired fasting glucose and MetS risk.⁵

Dogadin et al.’s northern Siberia T2D prevalence study reported lower diagnosed T2D in northern indigenous peoples than in southern/central Siberian populations and northern non-indigenous populations.⁶ The search result summary reported northern indigenous prevalence of 2.54 per 1000 versus 8.98 per 1000 in northern non-indigenous inhabitants, and concluded that T2D remained rare among northern indigenous Siberian populations.⁶

Recent Yakutia studies suggest that this older low-diabetes pattern may be changing.⁷ A 2025 Central Yakutia rural study reported MetS prevalence of 28.1%, with risk tied to obesity, abdominal obesity, hypertension, smoking, age, education, and occupation.⁷ This supports a nutrition-transition model: population history, high-latitude environment, diet, physical activity, and lifestyle transition may shape observed metabolism, but this page does not establish a genetic cold-adaptation mechanism.⁵⁷

Tatar T2D, MetS, and Inflammation Evidence

Tatar-specific studies provide the clearest immune/inflammation-related T2D evidence found in this search.³⁴

Kochetova et al. 2019 studied chemokine-gene polymorphisms in 440 Tatar T2D patients and 500 Tatar controls from Bashkortostan.⁴ It found:

• CCL20 rs6749704 associated with T2D, OR 2.77.⁴
• CCL5 rs2107538 associated with T2D, OR 1.80.⁴
• CCL11 rs1696941 associated with T2D onset age, disease duration, and HbA1c.⁴
• CCL17 rs223828 and CCL20 rs6749704 correlated with obesity/BMI; CCL17 also associated with postprandial glucose and HbA1c.⁴

Kochetova et al. 2022 studied MetS in Tatars and found:³

• TNFRSF1B rs1061624 associated with MetS and TNF-alpha level.³
• TNFA rs1800629 associated with TNF-alpha and albuminuria.³
• CRP rs2794521/rs1130864 and CRP haplotypes associated with hsCRP, HOMA-IR, HbA1c, fasting/postprandial insulin, BMI, WHR, and lipid traits.³

Interpretation: These papers support chemokine/TNF/CRP pathways as plausible Tatar T2D/MetS inflammatory axes.³⁴ They do not establish whether Tatars differ from Chechens or Yakuts in PBMC composition or expression.¹⁰ They are useful for generating PBMC hypotheses: for example, whether Tatar T2D samples show stronger monocyte/chemokine or TNF/NF-kB signatures.³⁴

Chechen / North Caucasus T2D Paradox

The strongest recurring Chechen/North Caucasus pattern is high BMI/body-size measures with low carbohydrate-metabolism disorder prevalence.²¹

• Markelova et al. found Chechens had the highest BMI and obesity-related phenotypic measures among Chechens, Tatars, and Yakuts.²
• Kononenko et al. found North Caucasus peoples had the lowest carbohydrate-metabolism disorder prevalence despite higher BMI than Volga peoples.¹

This raises a hypothesis of different obesity-risk translation: the same BMI burden may not produce the same glycemic disorder prevalence across Russian ancestry groups.²¹ Possible explanations include body-fat distribution, diet/physical activity, genetic protection, ascertainment, age structure, historical territory effects, or unmeasured socioeconomic/environmental variables.¹¹⁰ Published sources do not resolve this; the PBMC project can test whether Chechen obesity is accompanied by weaker, different, or compensated inflammatory states.²¹

Relevance To The PBMC Project

The T2D PBMC ancestry paper should treat T2D differences as a multi-layer problem:

• Genetic mechanism layer: pPGS-defined beta-cell/lipid versus obesity/insulin-resistance mechanisms differ by ancestry in the same cohort.²
• Clinical layer: lipids, BP, BMI, WHR, and atherogenic index differ by ancestry and within T2D.²
• Epidemiology layer: Russian ethnic groups differ in carbohydrate-metabolism disorder prevalence and in how risk factors map onto disease.¹
• Immune layer: direct Russian ancestry-stratified PBMC evidence is missing; Tatar candidate-gene studies provide pathway hypotheses rather than direct PBMC evidence.³⁴¹⁰

The strongest manuscript-safe claim is: Published literature and same-cohort genotyping show ancestry-associated T2D prevalence, metabolic-risk, and pPGS-profile differences across Russian populations, but ancestry-specific PBMC immune differences remain to be directly tested in the current project.²¹³⁴

Candidate PBMC Hypotheses

• Yakut T2D may show immune correlates of beta-cell/lipid pPGS or lipid/BP clinical profiles rather than obesity-driven inflammation, but this is a testable hypothesis, not a current result.²⁸
• Chechen T2D or high-BMI controls may help test whether high BMI is decoupled from glycemic and inflammatory PBMC signatures.²¹
• Tatar T2D may be enriched for CRP/TNF/chemokine-linked inflammatory programs suggested by candidate-gene studies.³⁴
• Lipid variables (LDL, HDL, total cholesterol, triglycerides, atherogenic index) should be modeled as possible mediators of PBMC differences, especially in Yakut T2D.²
• Blood pressure and medication exposure should be modeled because Markelova et al. found ancestry-by-T2D differences in BP and lipid traits.²

Evidence Gaps

• No source found directly compares Chechen, Tatar, and Yakut PBMC composition or single-cell gene expression in T2D.¹⁰
• Chechen-specific T2D immune or inflammatory-marker literature appears sparse.¹⁰
• Tatar immune/T2D evidence is candidate-gene heavy and may not replicate in unbiased transcriptomic or cellular assays.³⁴
• Yakut T2D evidence mixes older low-diabetes rural data with newer metabolic-transition studies, so temporal and lifestyle context is critical.⁵⁷
• Broad NATION ethnic groups do not map perfectly onto individual ancestries: Volga peoples are not identical to Tatars, and North Caucasus peoples are not identical to Chechens.¹

Related

• Russian Ancestry Groups: Phenotype, Blood, Immunity, and Disease Differences — broader phenotype and immune-context synthesis
• Ancestry-Specific T2D Genetic Mechanisms × PBMC Immune Changes — same-cohort pPGS/PBMC interpretation caveats
• East Asian β-Cell Dysfunction × Ancestry-Associated Immune Differences — population-level beta-cell mechanism framing

Reusable Footnotes

Sources Consulted

• Markelova, E. E., et al. (2025). Genetic and phenotypic heterogeneity of type 2 diabetes across Russian ancestry groups. Frontiers in Endocrinology, 16, 1672403. https://doi.org/10.3389/fendo.2025.1672403
• Kononenko, I. V., Shestakova, M. V., Elfimova, A. R., Khomyakova, I. A., Buzhilova, A. P., & Mokrysheva, N. G. (2022). Ethnic differences in risk factors and prevalence of type 2 diabetes in the adult population of the Russian Federation. Diabetes Mellitus, 25(5), 418-438. https://doi.org/10.14341/DM12935
• Snodgrass, J. J., et al. (2010). Impaired fasting glucose and the metabolic syndrome in an indigenous Siberian population. International Journal of Circumpolar Health, 69(1), 87-98. https://doi.org/10.3402/ijch.v69i1.17430
• Dogadin, S. A., et al. Prevalence of type 2 diabetes in northern populations of Siberia. Search result and abstract page: https://www.tandfonline.com/doi/abs/10.1080/25761900.2022.12220592
• Kochetova, O. V., Avzaletdinova, D. S., Morugova, T. V., & Mustafina, O. E. (2019). Chemokine gene polymorphisms association with increased risk of type 2 diabetes mellitus in Tatar ethnic group, Russia. Molecular Biology Reports, 46, 887-896. https://doi.org/10.1007/s11033-018-4544-6
• Kochetova, O. V., Avzaletdinova, D. S., & Korytina, G. F. (2022). Association of inflammation gene polymorphism with increased risk of metabolic syndrome in Tatar ethnic group. Russian Open Medical Journal, 11, e0305. https://doi.org/10.15275/rusomj.2022.0305

Footnotes

1. Kononenko et al. 2022, https://www.dia-endojournals.ru/jour/article/view/12935/0?locale=en_US ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴ ↩²⁵ ↩²⁶ ↩²⁷ ↩²⁸

2. Markelova et al. 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12457129/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴ ↩²⁵ ↩²⁶ ↩²⁷ ↩²⁸ ↩²⁹ ↩³⁰ ↩³¹ ↩³² ↩³³ ↩³⁴ ↩³⁵ ↩³⁶ ↩³⁷ ↩³⁸

3. Kochetova et al. 2022, https://romj.org/2022-0305 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴

4. Kochetova et al. 2019, https://link.springer.com/article/10.1007/s11033-018-4544-6 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵

5. Snodgrass et al. 2010, https://pubmed.ncbi.nlm.nih.gov/20167159/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

6. Dogadin et al., Prevalence of type 2 diabetes in northern populations of Siberia, https://www.tandfonline.com/doi/abs/10.1080/25761900.2022.12220592 ↩ ↩² ↩³

7. Central Yakutia rural metabolic syndrome study, https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2025/5/1230549482025051021 ↩ ↩² ↩³ ↩⁴ ↩⁵

8. Yabe et al. 2015, https://doi.org/10.1186/s12933-015-0195-7 ↩ ↩² ↩³ ↩⁴

9. Tarskaia et al. 2002, https://link.springer.com/article/10.1023/A:1015547432044 ↩

10. Human immune diversity review, https://www.nature.com/articles/s41590-021-01058-1 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶